1 |
Brandon, E. F., Sparidans, R. W., Guijt, K. J., Lowenthal, S., Meijerman, I., Beijnen, J. H. and Schellens, J. H. (2006) In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectedin), a novel marine anti-cancer drug. Invest. New Drugs 24, 3-14.
DOI
|
2 |
Debbab, A., Aly, A. H., Lin, W. H. and Proksch, P. (2010) Bioactive compounds from marine bacteria and fungi. Microb. Biotechnol. 3, 544-563.
DOI
|
3 |
Deng, C., Pan, B. and O'Connor, O. A. (2013) Brentuximab Vedotin. Clin. Cancer Res. 19, 22-27.
DOI
|
4 |
Burgess, J. G. (2012) New and emerging analytical techniques for marine biotechnology. Curr. Opin. Biotechnol. 23, 29-33.
DOI
|
5 |
Caron, D. A., Countway, P. D., Jones, A. C., Kim, D. Y. and Schnetzer, A. (2012) Marine protistan diversity. Ann. Rev. Mar. Sci. 4, 467-493.
DOI
|
6 |
Carter, N. J. and Keam, S. J. (2010) Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 70, 355-376.
|
7 |
Census of marine life [Internet] Office of Marine Programs, University of Rhode Island, Graduate School of Oceanography; c2010 [cited 2016 Aug 03]. Available from: http://www.coml.org/.
|
8 |
Cheung, R. C., Ng, T. B., Wong, J. H., Chen, Y. C. and Chan, W. Y. (2016) Marine natural products with anti-inflammatory activity. Appl. Microbiol. Biotechnol. 100, 1645-1666.
DOI
|
9 |
Chini Zitelli, G., Lavista, F., Bastianini, A., Rodolfi, L., Vincenzini, M. and Tredici, M. R. (1999) Production of eicosapentaenoic acid by Nannochloropsis sp. cultures in outdoor tubular photobioreactors. J. Biotechnol. 70, 299-312.
DOI
|
10 |
Cline, J., Braman, J. C. and Hogrefe, H. H. (1996) PCR fidelity of Pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res. 24, 3546-3551.
DOI
|
11 |
Council of Europe (2014) European Pharmacopoeia (Ph. Eur.) (8th edition). Council of Europe.
|
12 |
Cuevas, C. and Francesch, A. (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 26, 322-337.
DOI
|
13 |
Harris, J. R. and Markl, J. (1999) Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30, 597-623.
DOI
|
14 |
Fromm, J. R., McEarchem, J. A., Kennedy, D., Thomas, A., Shustov, A. R. and Gopal, A. K. (2012) Clinical binding properties, internalization kinetics, and clinic-pathological activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin. Lymphoma Myeloma Leuk. 12, 280-283.
DOI
|
15 |
Garnock-Jones, K. P. (2013) Brentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs 73, 371-381.
DOI
|
16 |
Giddings, L. A. and Newman, D. J. (2013) Microbial natural products: molecular blue-prints for antitumor drugs. J. Ind. Microbiol. Biotechnol. 40, 1181-1210.
DOI
|
17 |
Gross, H. (2009) Genomic mining - a concept for the discovery of new bioactive natural products. Curr. Opin. Drug Discov. Devel. 12, 207-219.
|
18 |
Grosso, F., D'Incalci, M., Cartaoafa, M., Nieto, A., Fernandez-Teruel, C., Alfaro, V., Lardelli, P., Roy, E., Gomez, J., Kahatt, C., Soto-Matos, A. and Judson, I. (2012) A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother. Pharmacol. 69, 1557-1565.
DOI
|
19 |
Hart, J. B., Lill, R. E., Hickford, S. J. H., Blunt, J. W. and Munro, M. H. G. (2000) The halichondrins: chemistry, biology, supply and delivery. In Drugs from the Sea (N. Fusetani, Ed.), pp. 134-153. Karger, Basel.
|
20 |
Hill, R. T. and Fenical, W. (2010) Pharmaceuticals from marine natural products: surge or ebb? Curr. Opin. Biotechnol. 21, 777-779.
DOI
|
21 |
Faulkner, D. J., Harper, M. K., Haygood, M. G., Salomon, C. E. and Schmidt, E. W. (2000) Symbiotic bacteria in sponges: sources of bioactive substances. In Drugs from the Sea (N. Fusetani, Ed.), pp. 107-119. Karger, Basel.
|
22 |
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F. and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17, 114-124.
DOI
|
23 |
D'Incalci, M., Badri, N., Galmarini, C.M. and Allavena, P. (2014) Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br. J. Cancer 111, 646-650.
DOI
|
24 |
Engene, N., Tronholm, A., Salvador-Reyes, L. A., Luesch, H. and Paul, V. J. (2015) Caldora penicillata gen. nov., comb. nov. (Cyanobacteria), a pantropical marine species with biomedical relevance. J. Phycol. 51, 670-681.
DOI
|
25 |
Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K. and Potts, B. C. (2009) Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 17, 2175-2180.
DOI
|
26 |
Kamat, P. K., Rai, S., Swarnkar, S., Shukla, R. and Nath, C. (2014) Molecular and cellular mechanisms of okadaic acid (OKA)-induced neurotoxicity: a novel tool of Alzheimer's disease therapeutic application. Mol. Neurobiol. 50, 852-865.
DOI
|
27 |
Hu, G. P., Yuan, J., Sun, L., She, Z. G., Wu, J. H., Lan, X. J., Zhu, X., Lin, Y. C. and Chen, S. P. (2011) Statistical research on marine natural products based on data obtained between 1985 and 2008. Mar. Drugs 9, 514-525.
DOI
|
28 |
Hu, Y., Chen, J., Hu, G., Yu, J., Zhu, X., Lin, Y., Chen, S. and Yuan, J. (2015) Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012. Mar. Drugs 13, 202-221.
DOI
|
29 |
Jensen, P. R. and Fenical, W. (2000) Marine microorganisms and drug discovery: current status and future potential. In Drugs from the Sea (N. Fusetani, Ed.), pp. 6-29. Karger, Basel.
|
30 |
Kiuru, P., D'Auria, M. V., Muller, C. D., Tammela, P., Vuorela, H. and Yli-Kauhaluoma, J. (2014) Exploring marine resources for bioactive compounds. Planta Med. 80, 1234-1246.
DOI
|
31 |
Klotz, U. (2006) Ziconotide - a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - a short review. Int. J. Clin. Pharmacol. Ther. 44, 478-483.
DOI
|
32 |
Koski, R. R. (2008) Omega-3-acid ethyl esters (lovaza) for severe hypertriglyceridemia. P T 33, 271-303.
|
33 |
Konig, G. M. (1992) Meeresorganismen als Quelle pharmazeutisch bedeutsamer Naturstoffe. Dtsch. Apoth. Ztg. 132, 673-683.
|
34 |
Miljanich, G. P. (2004) Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11, 3029-3040.
DOI
|
35 |
Mayer, A. M., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C. and Shuster, D. E. (2010) The odyssee of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31, 255-265.
DOI
|
36 |
Mayer, A. M. S. (2016) Marine pharmaceuticals: the clinical pipeline. [cited 2016 Aug 01] Available from: http://marinepharmacology.midwestern.edu/clinPipeline.htm/.
|
37 |
Mendola, D. (2000) Aquacultural production of bryostatin 1 and ecteinascidin 743. In Drugs from the Sea (N. Fusetani, Ed.), pp. 120-133. Karger, Basel.
|
38 |
Mocz, G. (2007) Fluorescent proteins and their use in marine biosciences, biotechnology, and proteomics. Mar. Biotechnol. 9, 305-328.
DOI
|
39 |
Molinski, T. F., Dalisay, D. S., Lievens, S. L. and Saludes, J. P. (2009) Drug development from marine natural products. Nat. Rev. Drug Discov. 8, 69-85.
DOI
|
40 |
Morris, P. G. (2010) Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs 21, 885-889.
DOI
|
41 |
Lindequist, U. and Schweder, T. (2001) Marine Biotechnology. In Biotechnology, Vol. 10: Special processes (H. J. Rehm, Ed.), pp. 441-484. Wiley-VCH, Weinheim.
|
42 |
Mullis, K. B. and Falcona, F. A. (1987) Specific synthesis of DNA in vitro via a polymerase-catalyzed chain-reaction. Meth. Enzymol. 155, 335-350.
DOI
|
43 |
Mutschler, E., Geisslinger, G., Menzel, S., Ruth, P. and Schmidtko, A. (2016) Pharmakologie kompakt: Allgemeine und Klinische Pharmakologie, Toxikologie. Wissenschaftliche Verlagsgesellschaft Stuttgart. German.
|
44 |
Newman, D. J. and Cragg, G. M. (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 67, 1216-1238.
DOI
|
45 |
Leal, M. C., Madeira, C., Brandao, C. A., Puga, J. and Calado, R. (2012) Bioprospecting of marine invertebrates for new natural products - a chemical and zoogeographical perspective. Molecules 17, 9842-9854.
DOI
|
46 |
Li, X. and Qin, L. (2005) Metagenomics-based drug discovery and marine microbial diversity. Trends Biotechnol. 23, 539-543.
DOI
|
47 |
Luesch, H., Moore, R. E., Paul, V. J., Mooberry, S. L. and Corbett, T. H. (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 64, 907-910.
DOI
|
48 |
Lopez-Guerrero, J. A., Romero, I. and Poveda, A. (2015) Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin. J. Cancer 34, 41-49.
|
49 |
Lowenberg, B. (2013) Sense and nonsense of high-dose cyatarabine for acute myeloid leukemia. Blood 121, 26-28.
DOI
|
50 |
Marmann, A., Aly, A. H., Lin, W., Wang, B. and Proksch, P. (2014) Co-cultivation - a powerful emerging tool for enhancing the chemical diversity of micororganisms. Mar. Drugs 12, 1043-1065.
DOI
|
51 |
Martins, A., Vieira, H., Gaspar, H. and Santos, S. (2014) Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar. Drugs 12, 1066-1101.
DOI
|
52 |
Maruzzo, M., Brunello, A., Diminutto, A., Rastrelli, M. and Basso, U. (2016) Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline. Anticancer Drugs 27, 264-267.
DOI
|
53 |
Pean, E., Klaar, S., Berglund, E. G., Salmonson, T., Borregaard, J., Hofland, K. F., Ersboll, J., Abadie, E., Giuliani, R. and Pignatti, F. (2012) The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin. Cancer Res. 18, 4491-4497.
DOI
|
54 |
Newman, D. J. and Cragg, G. M. (2014) Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development. Mar. Drugs 12, 255-278.
DOI
|
55 |
Newman, D. J. and Cragg, G. M. (2016) Drugs and drug candidates from marine sources: an assessment of the current "state of play". Planta Med. 82, 775-789.
DOI
|
56 |
Olivera, B. M., Gray, W. R., Zeikus, R., McIntosh, J. M., Varga, J., Rivier, J., DeSantos, V. and Cruz, L. J. (1985) Peptide neurotoxins from fish-hunting cone snails. Science 230, 1338-1343.
DOI
|
57 |
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, D. A. and Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190-2196.
DOI
|
58 |
Sagar, S., Kaur, M. and Mineman, K. P. (2010) Antiviral lead compounds from marine sponges. Mar. Drugs 8, 2619-2638.
DOI
|
59 |
Radjasa, O. K., Vaske, Y. M., Navarro, G., Vervoort, H. C., Tenney, K., Linington, R. G. and Crews, P. (2011) Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants. Bioorg. Med. Chem. 19, 6658-6674.
DOI
|
60 |
Ramasamy, M. S., Arumugam, P., Manikandan, S. and Murugan, A. (2011) Molecular and combinatorial array of therapeutic targets from conotoxins. Am. J. Drug Discovery Dev. 1, 49-57.
DOI
|
61 |
Schofield, M. M., Jain, S., Porat, D., Dick, G. J. and Sherman, D. H. (2015) Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET-743. Environ. Microbiol. 17, 3964-3975.
DOI
|
62 |
Schweder, T., Lindequist, U. and Lalk, M. (2005) Screening for new metabolites from marine microorganisms. In Advances in Biochemical Engineering/Biotechnology, Vol. 96: Marine Biotechnology (Y. LeGal and R. Ulber, Eds.), pp. 1-48. Springer, Berlin, Heidelberg.
|
63 |
Shimomura, O. (2009) Discovery of green fluorescent protein (GFP) (Nobel lecture). Angew. Chem. Int. Ed. Engl. 48, 5590-5602.
DOI
|
64 |
Skropeta, D. (2008) Deep-sea natural products. Nat. Prod. Rep. 25, 1131-1166.
DOI
|
65 |
World Register of Marine Species [Internet] WoRMS Editorial Board; 2016 [cited 2016 Aug 03]. Available from: http://www.marinespecies.org/.
|
66 |
Smith, J. A., Wilson, L., Azarenko, O., Zhu, X., Lewis, B. M., Littlefield, B. A. and Jordan, M. A. (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49, 1331-1337.
DOI
|
67 |
Snelgrove, P. V. (2016) An ocean of discovery: biodiversity beyond the Census of Marine Life. Planta Med. 82, 790-799.
DOI
|
68 |
Suleria, H. A., Osborne, S., Masci, P. and Gobe, G. (2015) Marinebased nutraceuticals: an innovative trend in the food and supplement industries. Mar. Drugs 13, 6336-6351.
DOI
|
69 |
Weinheimer, A. J. and Spraggins, R. L. (1969) The occurrence of two new prostaglandin derivatives (15-epi-PGA2 and its acetate, methyl ester) in the gorgonian Plexaura homomalla chemistry of coelenterates. XV. Tetrahedron Lett. 10, 5185-5188.
DOI
|
70 |
Witte, A. V., Kerti, L., Hermannstadter, H. M., Fiebach, J. B., Schreiber, S. J., Schuchardt, J. P., Hahn, A. and Floel, A. (2014) Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb. Cortex 24, 3059-3068.
DOI
|
71 |
Wu, C. H. (2009) Palytoxin: membrane mechanisms of action. Toxicon 54, 1183-1189.
DOI
|
72 |
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., Forero-Torres, A., Moskowitz, C. H., Connors, J. M., Engert, A., Larsen, E. K., Kennedy, D. A., Sievers, E. L. and Chen, R. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189.
DOI
|
73 |
Terlau, H. and Olivera, B. M. (2004) Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. 84, 41-68.
DOI
|
74 |
Proksch, P., Putz, A., Ortlepp, S., Kjer, J. and Bayer, M. (2010) Bioactive natural products from marine sponges and fungal endophytes. Phytochem. Rev. 9, 475-489.
DOI
|
75 |
Perez-Victoria, I., Martin, J. and Reyes, F. (2016) Combined LC/UV/MS and NMR strategies for the dereplication of marine natural products. Planta Med. 82, 857-871.
DOI
|
76 |
Sutherland, M. S., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., Senter, P. D., Law, C. L. and Wahl, A. F. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281, 10540-10547.
DOI
|
77 |
Takeyama, H., Takeda, D., Yazawa, K., Yamada, A. and Matsunaga, T. (1997) Expression of the eicosapentaenoic acid synthesis gene cluster from Shewanella sp. in a transgenic marine cyanobacterium, Synechococcus sp. Microbiology 143, 2725-2731.
DOI
|
78 |
Tarman, K., Lindequist, U. and Mundt, S. (2013) Metabolites of marine microorganisms and their pharmacological activities. In Marine Microbiology: Bioactive Compounds and Biotechnological Applications (S. K. Kim, Ed.), pp. 393-415. Wiley-VCH, Weinheim.
|
79 |
Teuscher, E. and Lindequist, U. (2010) Biogene Gifte. Wissenschaftliche Verlagsgesellschaft, Stuttgart. German.
|
80 |
Thomas, N. V. and Kim, S. K. (2013) Beneficial effects of marine algal compounds in cosmeceuticals. Mar. Drugs 11, 146-164.
DOI
|
81 |
Bane, V., Lehane, M., Dikshit, M., O'Riordan, A. and Furey, A. (2014) Tetrodotoxin: chemistry, toxicity, source, distribution and detection. Toxins 6, 693-755.
DOI
|
82 |
Anjum, K., Abbas, S. Q., Shah, S. A., Akhter, N., Batool, S. and Hassan, S. S. (2016) Marine sponges as drug treasure. Biomol.Ther. (Seoul) 24, 347-362.
DOI
|
83 |
Aicher, T. D., Buszek, K. R., Fang, F. G., Forsyth, C. J., Jung, S. H., Kishi, Y., Matelich, M. C., Scola, P. M., Spero, D. M. and Yoon, S. K. (1992) Total synthesis of halichondrin B and norhalichondrin B. J. Am. Chem. Soc. 114, 3162-3164.
DOI
|
84 |
Ansell, S. M. (2011) Brentuximabvedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin. Investig. Drugs 20, 99-105.
DOI
|
85 |
Bergmann, W. and Burke, D. C. (1955) Marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine. J. Org. Chem. 20, 1501-1507.
DOI
|
86 |
Bergmann, W. and Feeney, R. J. (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges. J. Org. Chem. 16, 981-987.
DOI
|
87 |
Blunt, J. W., Copp, B. R., Keyzers, R. A., Munro, M. H. and Prinsep, M. R. (2016) Marine natural products. Nat. Prod. Rep. 33, 382-431.
DOI
|
88 |
Bogdanov, A. M., Mishin, A. S., Yampolsky, I. V., Belousov, V. V., Chudakov, D. M., Subach, F. V., Verkhusha, W., Lukyanov, S. and Lukyanov, K. A. (2009) Green fluorescent proteins are light-induced electron donors. Nat. Chem. Biol. 5, 459-461.
DOI
|
89 |
Bongiorni, L. and Pietra, F. (1996) Marine natural products for industrial applications. Chem. Ind. 2, 54-58.
|